Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Isocitrate dehydrogenase (IDH) 1 and 2 mutations result in overproduction of D-2-hydroxyglutarate (2-HG) and impaired cellular differentiation. Ivosidenib, a targeted mutant IDH1 (mIDH1) enzyme inhibitor, can restore normal differentiation and results in clinical responses in a subset of patients wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Choe, Sung, Wang, Hongfang, DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Roboz, Gail J., Altman, Jessica K., Mims, Alice S., Watts, Justin M., Pollyea, Daniel A., Fathi, Amir T., Tallman, Martin S., Kantarjian, Hagop M., Stone, Richard M., Quek, Lynn, Konteatis, Zenon, Dang, Lenny, Nicolay, Brandon, Nejad, Parham, Liu, Guowen, Zhang, Vickie, Liu, Hua, Goldwasser, Meredith, Liu, Wei, Marks, Kevin, Bowden, Chris, Biller, Scott A., Attar, Eyal C., Wu, Bin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7218420/
https://ncbi.nlm.nih.gov/pubmed/32380538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001503
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados